ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

During the last years, there has been a dramatic increase in the administrative and bureaucratic burden associated with clinical research, which has clearly had an impact on its overall efficiency and on the activity of clinical investigators and research teams. Indeed, the supervision of the adherence of clinical research to Good Clinical Practice (GCP) guidelines and legal regulations is of the utmost importance. Yet, while such regulations have remained largely unchanged during recent years, the number of administrative tasks and their complexity have grown markedly, as supported by the results of a survey performed among 940 clinical investigators that we report in this manuscript. Therefore, many investigators believe that it has become necessary to undertake a rigorous analysis of the causes and consequences of this issue, and to create a conduit to channel the advice from experienced investigators regarding clinical research procedures, in order to improve them. Based on these premises, ESMO has launched the ESMO Clinical Research Observatory (ECRO), a task force that will analyse different aspects of clinical research. ECRO will aim to provide the views of ESMO on clinical research procedures based on the feedback from clinical investigators, under complete adherence to the Declaration of Helsinki, the GCP guidelines and any other applicable legal regulations, while at the same time showing profound respect for all the stakeholders involved in clinical research. This manuscript provides the background and rationale for the creation of ECRO, its planned activity and an analysis of the current administrative burden in clinical research with recommendations to rationalise it. Indeed, we expect that this effort shall lead to a relevant improvement in the care of patients and in the development of clinical research.

[1]  F. Ciardiello,et al.  Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer , 2019, ESMO Open.

[2]  S. Rule,et al.  Bureaucracy is strangling clinical research , 2019, BMJ.

[3]  D. Galetta,et al.  Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer , 2017, Clinical lung cancer.

[4]  Edward S. Kim,et al.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Caroline Schenkel,et al.  Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Richard Pazdur,et al.  Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Xian-Jin Xie,et al.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  D. Lacombe,et al.  Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients , 2017, ESMO Open.

[9]  R. Labianca,et al.  A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Dooms,et al.  The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database. , 2016, Lung cancer.

[11]  F. Shepherd,et al.  Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  C. Dooms,et al.  Lung cancer at the intensive care unit: The era of targeted therapy. , 2015, Lung cancer.

[13]  H. Kantarjian,et al.  Impact of cancer research bureaucracy on innovation, costs, and patient care. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Domján Andrea,et al.  World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects , 2014 .